Originalarbeiten

233. Pedro Cahn, Richard Kaplan, Paul E Sax, Kathleen Squires, ONCEMRK Study Group (including A. Stoehr):

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

The Lancet HIV, Volume 4, Issue 11, November 2017, Pages e486-e494

 

232. Berg T, Petersen J; FINITE [First investigation in stopping TDF treatment after long-term virological suppression in HBeAg-negative chronic hepatitis B]; study authors.:

Predicting long-term response after stopping nucleos(t)ide analogue treatment in HBeAg-negative chronic hepatitis B.

J Hepatol. 2017 Oct 6. pii: S0168-8278(17)32345-0. doi: 10.1016/j.jhep.2017.09.025. [Epub ahead of print] No abstract available. PMID: 28993185.

 

231. Jones D, Boudes PF, Swain MG, Bowlus CL, Galambos MR, Bacon BR, Doerffel Y, Gitlin N, Gordon SC, Odin JA, Sheridan D, Wörns MA, Clark V, Corless L, Hartmann H, Jonas ME, Kremer AE, Mells GF, Buggisch P, Freilich BL, Levy C, Vierling JM, Bernstein DE, Hartleb M, Janczewska E, Rochling F, Shah H, Shiffman ML, Smith JH, Choi YJ, Steinberg A, Varga M, Chera H, Martin R, McWherter CA, Hirschfield GM.:

Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.

Lancet Gastroenterol Hepatol. 2017 Oct;2(10):716-726. doi: 10.1016/S2468-1253(17)30246-7. Epub 2017 Aug 14. PMID: 28818518.

 

230. Berg T, Simon KG, Mauss S, Schott E, Heyne R, Klass DM, Eisenbach C, Welzel TM, Zachoval R, Felten G, Schulze-Zur-Wiesch J, Cornberg M, Op den Brouw ML, Jump B, Reiser H, Gallo L, Warger T, Petersen J; FINITE CHB study investigators [First investigation in stopping TDF treatment after long-term virological suppression in HBeAg-negative chronic hepatitis B].:

Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.

J Hepatol. 2017 Jul 21. pii: S0168-8278(17)32155-4. doi: 10.1016/j.jhep.2017.07.012. [Epub ahead of print] PMID: 28736139.

 

229. Janssen HLA, Chan HLY, Petersen J.:

Hepatitis B virus infection.

Best Pract Res Clin Gastroenterol. 2017 Jun;31(3):237. doi: 10.1016/j.bpg.2017.05.009. Epub 2017 Jun 9. No abstract available. PMID: 28774404.

 

228. Dandri M, Petersen J.:

Animal models of HBV infection.

Best Pract Res Clin Gastroenterol. 2017 Jun;31(3):273-279. doi: 10.1016/j.bpg.2017.04.014. Epub 2017 May 5. Review. PMID: 28774409.

 

227. Giersch K, Homs M, Volz T, Helbig M, Allweiss L, Lohse AW, Petersen J, Buti M, Pollicino T, Sureau C, Dandri M, Lütgehetmann M.:

Both interferon alpha and lambda can reduce all intrahepatic HDV infection markers in HBV/HDV infected humanized mice.

Sci Rep. 2017 Jun 16;7(1):3757. doi: 10.1038/s41598-017-03946-9. PMID: 28623307.

 

226. Bourlière M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, Bansal MB, de Lédinghen V, Hyland RH, Stamm LM, Dvory-Sobol H, Svarovskaia E, Zhang J, Huang KC, Subramanian GM, Brainard DM, McHutchison JG, Verna EC, Buggisch P, Landis CS, Younes ZH, Curry MP, Strasser SI, Schiff ER, Reddy KR, Manns MP, Kowdley KV, Zeuzem S; POLARIS-1 and POLARIS-4 Investigators.:

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.

N Engl J Med. 2017 Jun 1;376(22):2134-2146. doi: 10.1056/NEJMoa1613512. PMID: 28564569.

 

225. Welzel TM, Hinrichsen H, Sarrazin C, Buggisch P, Baumgarten A, Christensen S, Berg T, Mauss S, Teuber G, Stein K, Deterding K, van Bömmel F, Heyne R, John C, Zimmermann T, Lutz T, Schott E, Hettinger J, Kleine H, König B, Hüppe D, Wedemeyer H.:

Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry.

J Viral Hepat. 2017 Oct;24(10):840-849. doi: 10.1111/jvh.12708. Epub 2017 May 25. PMID: 28342229.

 

224. Allweiss L, Volz T, Giersch K, Kah J, Raffa G, Petersen J, Lohse AW, Beninati C, Pollicino T, Urban S, Lütgehetmann M, Dandri M.:

Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo.

Gut. 2017 Apr 20. pii: gutjnl-2016-312162. doi: 10.1136/gutjnl-2016-312162. [Epub ahead of print] PMID: 28428345.

 

223. Kowdley KV, Sundaram V, Jeon CY, Qureshi K, Latt NL, Sahota A, Lott S, Curry MP, Tsai N, Chaiyakunapruk N, Lee Y, Petersen J, Buggisch P.:

Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection.

Hepatology. 2017 Apr;65(4):1094-1103. doi: 10.1002/hep.29005. Epub 2017 Feb 25. Review. PMID: 28027579.

 

222. Bourgeois S, Van Vlierberghe H, Moreno C, Orlent H, Nevens F, Arastéh K, Horsmans Y, Schattenberg JM, Buggisch P, Francque S, Vijgen L, Kakuda TN, Hoeben E, Luo D, Vandebosch A, Jacquemyn B, Van Remoortere P, Verloes R.:

Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection.

BMC Gastroenterol. 2017 Feb 10;17(1):26. doi: 10.1186/s12876-017-0580-2. PMID: 28187751.

 

221. Hézode C, Almasio PL, Bourgeois S, Buggisch P, Brown A, Diago M, Horsmans Y, Serfaty L, Szalay F, Gaeta GB, Planas R, Schlag M, Lonjon-Domanec I, Omoruyi E, DeMasi R, Zeuzem S.:

Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease.

Liver Int. 2017 Sep;37(9):1304-1313. doi: 10.1111/liv.13376. Epub 2017 Mar 13. PMID: 28135777.

 

220. Cornberg M, Petersen J, Schober A, Mauss S, Böker KH, Link R, Günther R, Serfert Y, Pfeiffer-Vornkahl H, Manns MP, Sarrazin C, Hüppe D, Berg T, Niederau C.:

Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection.

Aliment Pharmacol Ther. 2017 Mar;45(5):688-700. doi: 10.1111/apt.13925. Epub 2017 Jan 12. PMID: 28078723.

 

219. Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster GR, Craxí A, Buggisch P, Sanai F, Bicer C, Lenz O, Van Dooren G, Nalpas C, Lonjon-Domanec I, Schlag M, Buti M.:

Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response.

PLoS One. 2017 Jan 5;12(1):e0168713. doi: 10.1371/journal.pone.0168713. eCollection 2017. PMID: 28056030.

 

218. P. Buggisch, P. Atanasov, K. Wursthorn, A. Stoehr, J. Petersen:

SAT-254: Real-world effectiveness and cost per SVR of Sofosbuvir/ Velpatasvir chronic hepatitis C treatment

Journal of Hepatology, Volume 66, Issue 1, Supplement, 2017, Page s730

 

217. J. Petersen, K. Wursthorn, K. Olah, T. Lorenzen, A. Plettenberg, S. Unger, C. Czaja-Harder, A. Burchard, K. Matschenz, A. Stoehr, P. Buggisch:

FRI-252 - Strong decrease of patients with advanced liver disease and more adherence problems to HCV therapy as DAA regimen enter third year of existence in Germany

Journal of Hepatology, Volume 66, Issue 1, Supplement, 2017, Page s522 DOI: http://dx.doi.org/10.1016/S0168-8278(17)31446-0

 

216. Rockstroh JK, Ingiliz P, Petersen J, Peck-Radosavljevic M, Welzel TM, Van der Valk M, Zhao Y, Jimenez-Exposito MJ, Zeuzem S.:

Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.

Antivir Ther. 2017;22(3):225-236. doi: 10.3851/IMP3108. Epub 2016 Nov 15. PMID: 27845298.

 

215. Marcellin P, Ahn SH, Chuang WL, Hui AJ, Tabak F, Mehta R, Petersen J, Lee CM, Ma X, Caruntu FA, Tak WY, Elkhashab M, Lin L, Wu G, Martins EB, Charuworn P, Yee LJ, Lim SG, Foster GR, Fung S, Morano L, Samuel D, Agarwal K, Idilman R, Strasser SI, Buti M, Gaeta GB, Papatheodoridis G, Flisiak R, Chan HL.:

Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B.

Aliment Pharmacol Ther. 2016 Nov;44(9):957-966. doi: 10.1111/apt.13779. Epub 2016 Sep 15. PMID: 27629859.

 

214. Welzel TM, Petersen J, Herzer K, Ferenci P, Gschwantler M, Wedemeyer H, Berg T, Spengler U, Weiland O, van der Valk M, Rockstroh J, Peck-Radosavljevic M, Zhao Y, Jimenez-Exposito MJ, Zeuzem S.:

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.

Gut. 2016 Nov;65(11):1861-1870. doi: 10.1136/gutjnl-2016-312444. Epub 2016 Sep 7. Erratum in: Gut. 2016 Dec;65(12 ):2060. PMID: 27605539.

 

213. Petersen J, Thompson AJ, Levrero M.:

Aiming for cure in HBV and HDV infection.

J Hepatol. 2016 Oct;65(4):835-48. doi: 10.1016/j.jhep.2016.05.043. Epub 2016 Jun 3. Review. PMID: 27270043.

 

212. Zoulim F, Białkowska-Warzecha J, Diculescu MM, Goldis AE, Heyne R, Mach T, Marcellin P, Petersen J, Simon K, Bendahmane S, Klauck I, Wasiak W, Janssen HL.:

Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure.

Hepatol Int. 2016 Sep;10(5):779-88. doi: 10.1007/s12072-016-9737-2. Epub 2016 May 20. PMID: 27206517.

 

211. Owens CM, Brasher BB, Polemeropoulos A, Rhodin MH, McAllister N, Peng X, Wang C, Ying L, Cao H, Lawitz E, Poordad F, Rondon J, Box TD, Zeuzem S, Buggisch P, Lin K, Qiu YL, Jiang L, Colvin R, Or YS.:

Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6207-15. doi: 10.1128/AAC.00808-16. Print 2016 Oct. PMID: 27503640.

 

210. Hüppe D, Buggisch P, Christensen S, Heiken H, Mauss S, Naumann U, Fischer C, Kleine H, Huelsenbeck J.:

Chronic hepatitis C patients prior to broad access to interferon-free treatments in Germany.

Z Gastroenterol. 2016 Aug;54(8):740-7. doi: 10.1055/s-0042-106731. Epub 2016 Aug 16. PMID: 27529525.

 

209. Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster GR, Craxí A, Buggisch P, Ryan R, Lenz O, Scott J, Van Dooren G, Lonjon-Domanec I, Schlag M, Buti M.:

An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1).

PLoS One. 2016 Jul 18;11(7):e0158526. doi: 10.1371/journal.pone.0158526. eCollection 2016. PubMed PMID: 27428331.

 

208. Tacke F, Günther R, Buggisch P, Klinker H, Schober A, John C, Lutz T, Pfeiffer-Vornkahl H, Niederau C, Cornberg M, Sarrazin C, Mauss S.:

Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower SVR rates in real life than expected from clinical trials.

Liver Int. 2016 Jul 18. doi: 10.1111/liv.13206. [Epub ahead of print] PubMed PMID: 27428297.

 

207 Fülöp B, Mihm U, Rohde P, Buggisch P, Schlosser B, Biermer M, Brodzinski A, Fischer J, Böhm S, van Bömmel F, Sarrazin C, Berg T.:

Hepatitis C viral dynamics during ribavirin priming differ according to prior treatment response and HCV type.

J Viral Hepat. 2016 Jun 26. doi: 10.1111/jvh.12562. [Epub ahead of print] PubMed PMID: 27346846.

 

206. Fischer J, Weber AN, Böhm S, Dickhöfer S, El Maadidi S, Deichsel D, Knop V, Klinker H, Möller B, Rasenack J, Wang L, Sharma M, Hinrichsen H, Spengler U, Buggisch P, Sarrazin C, Pawlita M, Waterboer T, Wiese M, Probst-Müller E, Malinverni R, Bochud PY, Gardiner CM, O'Farrelly C, Berg T.:

Sex-specific effects of TLR9 promoter variants on spontaneous clearance of HCV infection.

Gut. 2016 Apr 21. pii: gutjnl-2015-310239. doi: 10.1136/gutjnl-2015-310239. [Epub ahead of print] PubMed PMID: 27196570.

 

205. Maura Dandri, Joerg Petersen:

Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential.

CID 2016:62 (Suppl 4) S281.

 

204. George Papatheodoridis, Ioannis Vlachogiannakos, Evangelos Cholongitas, Karsten Wursthorn, Christos Thomadakis, Giota Touloumi, Jörg Petersen:

Discontinuation of Oral Antivirals in Chronic Hepatitis B: A Systematic Review.

HEPATOLOGY, VOL. 63, NO. 5, 2016.

 

203. Murray JM, Stancevic O, Lütgehetmann M, Wursthorn K, Petersen J, Dandri M.

J Theor Biol. 2016 Feb 21;391:74-80. doi: 10.1016/j.jtbi.2015.12.005. Epub 2015 Dec 23. PMID: 26723531.

 

202. P. Buggisch, K. Wursthorn, A. Stoehr, A. Gauthier, J. Petersen:

SAT-240: Real-World Effectiveness and Cost per Sustained Viral Response of Ledipasvir/Sofosbuvir Chronic Hepatitis C Treatment

Journal of Hepatology, Volume 64, Issue 2, Supplement, 2016, Pages s809-s810

 

201. P. Buggisch, K. Wursthorn, A. Stoehr, A. Gauthier, J. Petersen:

SAT-243: Real-World Effectiveness of Ledipasvir/Sofosbuvir 8 Weeks Chronic Hepatitis C Treatment

Journal of Hepatology, Volume 64, Issue 2, Supplement, 2016, Page s811

200. J.Petersen, K.Wursthorn, K.Olah, T.Lorenzen, A.Plettenberg, S.Unger, C.Czaja-Harder, K.Matschenz, A.Stoehr, P.Buggisch_

SAT-185: Failure with DAA Regimens in a High Volume Treatment Center under Real Life Conditions

Journal of Hepatology, Volume 64, Issue 2, Supplement, 2016, Page s782

 

199. Christian Hoffmann, Philipp Schommers, Eva Wolf, Markus Muller, Alexander Schultze , Ivanka Krznaric, Albrecht Stoehr , Timo Wolf , Gerd Faetkenheuer , Bastian Stier , Christoph Wyen, Marcus Hentrich:

CD4R and CD8R T-cell kinetics in aviremic HIV-infected patients developing Hodgkin or non-Hodgkin lymphoma

Christian Hoffmann, Philipp Schommers, Eva Wolf, Markus Muller, Alexander Schultze , Ivanka Krznaric, Albrecht Stoehr , Timo Wolf , Gerd Faetkenheuer , Bastian Stier , Christoph Wyen, Marcus Hentrich

 

198. Eugénio Teófilo, Nuno Rocha-Pereira, Birger Kuhlmann, Antonio Antela, Heribert Knechten, Jesús Santos, Maria Jesús Jiménez-Expósito, on behalf of the REMAIN study group (including A. Stoehr):

Long-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Naïve Patients with HIV-1 Infection: the REMAIN Study

HIV Clin Trials. 2016 Jan 2; 17(1): 17–28. Published online 2016 Feb 5. doi: 10.1080/15284336.2015.1112494

 

197. Cooper DA, Cordery DV, Zajdenverg R, Ruxrungtham K, Arastéh K, Bergmann F, Neto JL, Scherer J, Chaves RL, Robinson P; study team (including A. Stoehr):

Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.

PLoS One. 2016 Jan 5;11(1):e0144917. doi: 10.1371/journal.pone.0144917. eCollection 2016.

 

196. Lambert-Niclot S, George EC, Pozniak A, White E, Schwimmer C, Jessen H, Johnson M, Dunn D, Perno CF, Clotet B, Plettenberg A, Blaxhult A, Palmisano L, Wittkop L, Calvez V, Marcelin AG, Raffi F; NEAT 001/ANRS 143 Study Group.:

Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.

J Antimicrob Chemother. 2016 Apr;71(4):1056-62. doi: 10.1093/jac/dkv427. Epub 2015 Dec 24. PMID: 26702926

 

195. Friedrich-Rust M, Lupsor M, de Knegt R, Dries V, Buggisch P, Gebel M, Maier B, Herrmann E, Sagir A, Zachoval R, Shi Y, Schneider MD, Badea R, Rifai K, Poynard T, Zeuzem S, Sarrazin C:

Point Shear Wave Elastography by Acoustic Radiation Force Impulse Quantification in Comparison to Transient Elastography for the Noninvasive Assessment of Liver Fibrosis in Chronic Hepatitis C: A Prospective International Multicenter Study.

Ultraschall Med. 2015 May 13. [Epub ahead of print] PubMed PMID: 25970201.

 

194. Schmidt D, Kollan C, Stoll M, Stellbrink HJ, Plettenberg A, Fätkenheuer G, Bergmann F, Bogner JR, van Lunzen J, Rockstroh J, Esser S, Jensen BE, Horst HA, Fritzsche C, Kühne A, an der Heiden M, Hamouda O, Bartmeyer B; ClinSurv Study Group.:

From pills to patients: an evaluation of data sources to determine the number of people living with HIV who are receiving antiretroviral therapy in Germany.

BMC Public Health. 2015 Mar 17;15:252. doi: 10.1186/s12889-015-1598-4. PMID: 25848706

 

193. Sarrazin C, Berg T, Buggisch P, Dollinger MM, Hinrichsen H, Hofer H, Hüppe D, Manns MP, Mauss S, Petersen J, Simon KG, van Thiel I, Wedemeyer H, Zeuzem S:

[S3 guideline hepatitis C addendum]. Z Gastroenterol. 2015 Apr;53(4):320-34. doi: 10.1055/s-0034-1399322. Epub 2015 Apr 13. German. PubMed PMID: 25867048.

 

192. Fülöp B, Biermer M, Cornberg M, Wedemeyer H, Port K, Heyne R, Zeuzem S, Peiffer KH, Welzel T, Herber A, Buggisch P, Moser C, Stoll S, Alshuth U, Berg T:

Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders.

Liver Int. 2015 Mar 19. doi: 10.1111/liv.12832. [Epub ahead of print] PubMed PMID: 25801095.

 

191. Daniel Schmidt, Christian Kollan, Matthias Stoll, Hans-Jürgen Stellbrink, Andreas Plettenberg,
Gerd Fätkenheuer, Frank Bergmann, Johannes R Bogner, Jan van Lunzen, Jürgen Rockstroh, Stefan Esser,
Björn-Erik Ole Jensen, Heinz-August Horst, Carlos Fritzsche, Andrea Kühne, Matthias an der Heiden,
Osamah Hamouda, Barbara Bartmeyer and ClinSurv Study Group:

From pills to patients: an evaluation of data sources to determine the number of people living with HIV who are  receiving antiretroviral therapy in Germany

BMC Public Health (2015) 15:252 DOI 10.1186/s12889-015-1598-4

 

190. Jorg Petersen, Maura Dandri:

Optimal therapy for chronic hepatitis B: hepatitis B virus combination therapy?

Liver International 2015; 35 (Suppl. 1): 114–120

 

189. Maribel Rodriguez–Torres, Albrecht Stoehr, Edward J. Gane, Lawrence Serfaty, Eric Lawitz, Amy Zhou, Michael Bourque, Sanhita Bhanja, Julie Strizki, Richard J. O. Barnard, Peggy M. T. Hwang, Mark J. DiNubile, Niloufar Mobashery:

Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of SVR in Treatment-Experienced Patients With Chronic HCV Genotype 1 Infection and Cirrhosis.

Clinical Gastroenterology and Hepatology 2014; 12:1029–1037

 

188. Sarrazin C, Berg T, Buggisch P, Dollinger M, Hinrichsen H, Hüppe D, Manns M, Mauss S, Petersen J, Simon KG, van Thiel I, Wedemeyer H, Zeuzem S:

Aktuelle Empfehlung zur Therapie der chronischen Hepatitis C.

Z Gastroenterol. 2014 Oct;52(10):1185-97. German. PubMed PMID: 25513400.

 

187. Heidrich B, Wiegand SB, Buggisch P, Hinrichsen H, Link R, Möller B, Böker KH, Teuber G, Klinker H, Zehnter E, Naumann U, Busch HW, Maasoumy B, Baum U, Hardtke S, Manns MP, Wedemeyer H, Petersen J, Cornberg M; HepNet Study Group:

Treatment of naïve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA.

PLoS One. 2014 Oct 10;9(10):e108751. doi: 10.1371/journal.pone.0108751. eCollection 2014. PubMed PMID: 25302676; PubMed Central PMCID: PMC4193764.

 

186. Wiegand J, Maasoumy B, Buggisch P, Buslau A, Schiefke I, Berg T, Wedemeyer H, Sarrazin C, Hinrichsen H. Letter:

Telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis.

Aliment Pharmacol Ther. 2014 Jun;39(11):1342-4. doi: 10.1111/apt.12748. PubMed PMID: 24803258.

 

185. Thomas Harrer, Andreas Plettenberg, Keikawus Arastéh, Jan Van Lunzen, Gerd Fätkenheuer, Hans Jaeger, Michel Janssens, Wivine Burny, Alix Collard, François Roman, Alfred Loeliger, Marguerite Koutsoukos, Patricia Bourguignon, Ludo Lavreys, Gerald Voss:

Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: A randomised placebo-controlled study.

Vaccine, Volume 32, Issue 22, 7 May 2014, Pages 2657-2665

 

184. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P; ION-1 Investigators:

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

N Engl J Med. 2014 May 15;370(20):1889-98. doi: 10.1056/NEJMoa1402454. Epub 2014 Apr 11. PubMed PMID: 24725239.

 

183. Allweiss L, Volz T, Lütgehetmann M, Giersch K, Bornscheuer T, Lohse AW, Petersen J, Ma H, Klumpp K, Fletcher SP, Dandri M:

Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration.

J Hepatol. 2014 Mar; 60(3):500-7

 

182. Giersch K, Helbig M, Volz T, Allweiss L, Mancke LV, Lohse AW, Polywka S, Pollok JM, Petersen J, Taylor J, Dandri M, Lütgehetmann M:

Persistent hepatitis D virus mono-infection in humanized mice is efficiently converted by hepatitis B virus to a productive co-infection.

J Hepatol. 2014 Mar; 60(3):538-44

 

181. Grammatikos G, Lange C, Susser S, Schwendy S, Dikopoulos N, Buggisch P, Encke J, Teuber G, Goeser T, Thimme R, Klinker H, Boecher WO, Schulte-Frohlinde E, Penna-Martinez M, Badenhoop K, Zeuzem S, Berg T, Sarrazin C:

Vitamin D Levels Vary during Antiviral Treatment but Are Unable to Predict Treatment Outcome in HCV Genotype 1 Infected Patients.

PLOS ONE, 07 Feb 2014 ; 9(2):e87974

 

180. Marcellin P, Cooper C, Balart L, Larrey D,Box T, Yoshida E, Lawitz E, Buggisch P, Ferenci P, Weltman M, Labriola–Tompkins E, Le Pogam S, Nájera I, Thomas D, Hooper G, Shulman NS, Zhang Y, Navarro MT, Lim CY, Brunda M, Terrault NA, Yetzer ES:

Randomized Controlled Trial of Danoprevir Plus Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve Patients With Hepatitis C Virus Genotype 1 Infection.

Gastroenterology  2013 Oct. Vol. 145, Issue 4, Pages 790-800.e3

 

179. Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Dinh P, Martins EB, Yee LJ, Flaherty JF, Kitrinos KM, Rustgi VK, Marcellin P:

Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load.

Hepatology. 2013 Aug; 58(2):505-13

 

178. Klaus Jansen, Burkhard Haastert, Claudia Michalik, Adrienne Guignard, Stefan Esser, Stephan Dupke, Andreas Plettenberg, Adriane Skaletz-Rorowski, Norbert H Brockmeyer:

Incidence and risk factors of herpes zoster among hiv-positive patients in the german competence network for HIV/AIDS (KompNet): a cohort study analysis

BMC Infectious Diseases 2013, 13:372

 

177. Deterding K, Grüner N, Buggisch P, Wiegand J, Galle PR, Spengler U, Hinrichsen H, Berg T, Potthoff A, Malek N, Großhennig A, Koch A, Diepolder H, Lüth S, Feyerabend S, Jung MC, Rogalska-Taranta M, Schlaphoff V, Cornberg M, Manns MP, Wedemeyer H;:

Hep-Net Acute HCV-III Study Group. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial.

Lancet Infect Dis. 2013 Jun; 13(6):497-506

 

176. Zoutendijk R, Reijnders JG, Brown A, Zoulim F, Mutimer D, Deterding K, Petersen J, Peter Hofmann W, Buti M, Santantonio T, van Bömmel F, Pradat P, Oo Y, Luetgehetmann M, Berg T, Hansen BE, Wedemeyer H, Janssen HL; for the VIRGIL Surveillance Study Group:

Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response.

Hepatology. 2011 Aug;54(2):443-451

 

175. Zoutendijk R, Reijnders JG, Zoulim F, Brown A, Mutimer DJ, Deterding K, Hofmann WP, Petersen J, Fasano M, Buti M, Berg T, Hansen BE, Sonneveld MJ, Wedemeyer H, Janssen HL; VIRGIL Surveillance Study Group:

Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis.

Gut. 2013 May; 62(5):760-5

 

174. Volz T, Allweiss L, Ben MBarek M, Warlich M, Lohse AW, Pollok JM, Alexandrov A, Urban S, Petersen J, Lütgehetmann M, Dandri M:

The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus.

J Hepatol. 2013 May; 58(5):861-7

 

173. Friedrich-Rust M, Buggisch P, de Knegt RJ, Dries V, Shi Y, Matschenz K, Schneider MD, Herrmann E, Petersen J, Schulze F, Zeuzem S, Sarrazin C:

Acoustic radiation force impulse imaging for non-invasive assessment of liver fibrosis in chronic hepatitis B.

J Viral Hepat. 2013 Apr; 20(4):240-7

 

172. Burger D, Back D, Buggisch P, Buti M, Craxí A, Foster G, Klinker H, Larrey D, Nikitin I, Pol S, Puoti M, Romero-Gómez M, Wedemeyer H, Zeuzem S::

Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions.

J Hepatol. 2013 Apr; 58(4):792-800

 

171. Knop V, Teuber G, Klinker H, Möller B, Rasenack J, Hinrichsen H, Gerlach T, Spengler U, Buggisch P, Neumann K, Sarrazin C, Zeuzem S, Berg T::

Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy.

Ann Hepatol. 2013 Mar-Apr; 12(2):190-8

 

170. Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, Van Vlierberghe H, Trojan J, Kolligs FT, Weiss A, Miles S, Gasbarrini A, Lencioni M, Cicalese L, Sherman M, Gridelli C, Buggisch P, Gerken G, Schmid RM, Boni C, Personeni N, Hassoun Z, Abbadessa G, Schwartz B, Von Roemeling R, Lamar ME, Chen Y, Porta C:

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

Lancet Oncol. 2013 Jan; 14(1):55-63

 

169. Dandri M, Lütgehetmann M, Petersen J:

Experimental models and therapeutic approaches for HBV.

Semin Immunopathol. 2013 Jan; 35(1):7-21

 

168. Petersen J, Buti M:

Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs.

Expert Rev Gastroenterol Hepatol. 2012 Dec; 6(6):683-93

 

167. Schaefer M, Sarkar R, Knop V, Effenberger S, Friebe A, Heinze L, Spengler U, Schlaepfer T, Reimer J, Buggisch P, Ockenga J, Link R, Rentrop M, Weidenbach H, Fromm G, Lieb K, Baumert TF, Heinz A, Discher T, Neumann K, Zeuzem S, Berg T:

Escitalopram for the Prevention of Peginterferon-a2a-Associated Depression in Hepatits C Virus-Infected Patients Without Previous Psychiatric Disease: A Randomized Trial.

Ann Intern Med. 2012 Jul 17; 157(2):94-103

 

166. Zeuzem S, Buggisch P, Agarwal K, Marcellin P, Sereni D, Klinker H, Moreno C, Zarski JP, Horsmans Y, Mo H, Arterburn S, Knox S, Oldach D, McHutchison JG, Manns MP, Foster GR:

The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.

Hepatology. 2012 Mar; 55(3):749-58

 

165. Petersen J, Ratziu V, Buti M, Janssen HL, Brown A, Lampertico P, Schollmeyer J, Zoulim F.Wedemeyer H, Sterneck M, Berg T, Sarrazin C, Lutgehetmann M, Buggisch P:

Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis b patients: an international multicenter cohort study.

J Hepatol. 2012 Mar; 56(3):520-6

 

164. Lütgehetmann M, Mancke LV, Volz T, Helbig M, Allweiss L, Bornscheuer T, Pollok JM, Lohse AW, Petersen J, Urban S, Dandri M:

Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation.

Hepatology. 2012 Mar; 55(3):685-94

 

163. Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, Petersen J, Raimondo G, Dandri M, Levrero M:

IFN-a inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome.

J Clin Invest. 2012 Feb 1; 122(2):529-37

 

162. Cacoub P, Bourlière M, Lübbe J, Dupin N, Buggisch P, Dusheiko G, Hézode C, Picard O, Pujol R, Segaert S, Thio B, Roujeau JC:

Dermatological side effects of hepatitis C and its treatment: Patient management in the era of direct-acting antivirals.

J Hepatol. 2012 Feb; 56(2)

 

161. Volz T, Lütgehetmann M, Allweiss L, Warlich M, Bierwolf J, Pollok JM, Petersen J, Matthes E, Dandri M:

Strong antiviral activity of the new l-hydroxycytidine derivative, l-Hyd4FC, in HBV-infected human chimeric uPA/SCID mice.

Antivir Ther. 2012; 17(4):623-31

 

160. Wiegand J, Neumann K, Böhm S, Weich V, Teuber G, Klinker H, Möller B, Rasenack J, Hinrichsen H, Gerlach T, Spengler U, Buggisch P, Sarrazin C, Berg T:

Importance of minimal residual viremia for relapse prediction in patients with chronic hepatitis C genotype 1 infection.

Clin Infect Dis. 2011 Dec; 53(11):1111-4

 

159. Weich V, Herrmann E, Chung TL, Sarrazin C, Hinrichsen H, Buggisch P, Gerlach T, Klinker H, Spengler U, Bergk A, Zeuzem S, Berg T:

The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection.

J Gastroenterol. 2011 Dec; 46(12):1427-36

 

158. Petersen J:

HBV treatment and pregnancy.

J Hepatol. 2011 Dec; 55(6):1171-3

 

157. Sarrazin C, Schwendy S, Möller B, Dikopoulos N, Buggisch P, Encke J, Teuber G, Goeser T, Thimme R, Klinker H, Boecher WO, Schulte-Frohlinde E, Prinzing R, Herrmann E, Zeuzem S, Berg T:

Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks.

Gastroenterology. 2011 Nov; 141(5):1656-64

 

156. Petersen J:

[Hepatitis B in clinical practice].

Med Monatsschr Pharm. 2011 Nov; 34(11):402-14

 

155. Benten D, Schulze Zur Wiesch J, Sydow K, Koops A, Buggisch P, Böger RH, Gaydos CA, Won H, Franco V, Lohse AW, Ray SC, Balagopal A:

The transhepatic endotoxin gradient is present despite liver cirrhosis and is attenuated after transjugular portosystemic shunt (TIPS).

BMC Gastroenterol. 2011 Oct 6; 11:107

 

154. Grabowski J, Yurdaydìn C, Zachou K, Buggisch P, Hofmann WP, Jaroszewicz J, Schlaphoff V, Manns MP, Cornberg M, Wedemeyer H; HIDIT-1 study group:

Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment.

Liver Int. 2011 Oct; 31(9):1395-405

 

153. Manns M, Zeuzem S, Sood A, Lurie Y, Cornberg M, Klinker H, Buggisch P, Rossle M, Hinrichsen H, Merican I, Ilan Y, Mauss S, Abu-Mouch S, Horban A, Muller TH, Welsch C, Chen R, Faruqi R, Pedicone LD, Wedemeyer H:

Reduced Dose and Duration of Peginterferon alfa-2b and Weight-Based Ribavirin in Patients With Genotype 2 and 3 Chronic Hepatitis C.

 

152. Dandri M, Petersen J:

Chimeric Mouse Model of Hepatitis B Virus infection.

J Hepatol. 2011 Jul 26

 

151. Cornberg M, Protzer U, Petersen J, Wedemeyer H, Berg T, Jilg W, Erhardt A, Wirth S, Sarrazin C, Dollinger MM, Schirmacher P, Dathe K, Kopp IB, Zeuzem S, Gerlich WH, Manns MP; AWMF:

[Prophylaxis, diagnosis and therapy of hepatitis B virus infection - the German guideline].

Z Gastroenterol. 2011 Jul; 49(7):871-930

 

150. Lütgehetmann M, Bornscheuer T, Volz T, Allweiss L, Bockmann JH, Pollok JM, Lohse AW, Petersen J, Dandri M:

Hepatitis B virus limits response of human hepatocytes to interferon-a in chimeric mice.

Gastroenterology. 2011 Jun; 140(7):2074-83

 

149. Schulze Zur Wiesch J, Pudelski N, Hoepner L, Supplieth M, Buggisch P, Lohse AW, Lüth S:

"Real-Life" comparison of pegylated-interferon 2a versus 2b combination therapy of chronic hepatitis C virus.

Hepatology. 2011 Apr.; 53(4):1405-6; author reply 1407

 

148. Cornberg M, Protzer U, Petersen J, Wedemeyer H, Berg T, Jilg W, Erhardt A, Wirth A, Sarrazin C, Dollinger MM,  Schirmacher P, Dathe K, Kopp IB, Zeuzem S, Gerlich WH, Manns MP:

Aktualisierung der S3-Leitlinie zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion.

Z Gastroenterol 2011; 49: 871-930

 

147. Plettenberg A, Brockmeyer NH, Haastert B, Michalik C, Dupke S, Schewe K, Rausch M, Hower M, Ulmer A, Wolf E, Lorenzen T, Arendt G, Jansen K; the Competence Network for HIV/AIDS:

Impact of earlier HAART initiation on the immune status and clinical course of treated patients on the basis of cohort data of the German Competence Network for HIV/AIDS.

Infection 2011; 38 (1)

 

146. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Gurel S, Snow-Lampart A, Borroto-Esoda K, Mondou E, Anderson J, Sorbel J, Rousseau F:

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

Gastroenterology 2011; 140:132-43

 

145. Duprez DA, Neuhaus J, Tracy R, Kuller LH, Deeks SG, Orkin C, Stoehr A, Woolley IJ, Neaton JD; for the INSIGHT SMART Group:

N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients.

AIDS 2011; 15

 

144. Lutgehetmann M, Meyer F, Volz T, Lohse AW, Fischer C, Dandri M, Petersen J:

Knowledge about HBV, prevention behaviour and treatment adherence of patients with chronic hepatitis B in a large referral centre in Germany.

Z Gastroenterol. 2010 Sep.; 48(9):1126-32

 

143. Lutgehetmann M, Volz T, Köpke A, Broja T, Tigges E, Lohse AW, Fuchs E, Murray JM, Petersen J, Dandri M:

In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice.

Hepatology. 2010 Jul.; 52(1):16-24

 

142. Reijnders JG, Deterding K, Petersen J, Zoulim F, Santantonio T, Buti M, van Bömmel F, Hansen BE, Wedemeyer H, Janssen HL; VIRGIL Surveillance Study Group:

Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.

J Hepatol. 2010 Apr.; 52(4):493-500. Epub 2010 Feb 4

 

141. Urban S, Schulze A, Dandri M, Petersen J:

The replication cycle of hepatitis B virus.

J Hepatol. 2010 Feb.; 52(2):282-4. Epub 2009 Nov 24

 

140. Gehling UM, Willems M, Schlagner K, Benndorf RA, Dandri M, Petersen J, Sterneck M, Pollok JM, Hossfeld DK, Rogiers X:

Mobilization of hematopoietic progenitor cells in patients with liver cirrhosis.

World J Gastroenterol. 2010 Jan.; 16(2):217-24

 

139. van Bömmel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, Hüppe D, Stein K, Trojan J, Sarrazin C, Böcher WO, Spengler U, Wasmuth HE, Reinders JG, Möller B, Rhode P, Feucht HH, Wiedenmann B, Berg T:

Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues.

Hepatology. 2010 Jan.; 51(1):73-80

 

138. Moyle G, Boffito M, Stoehr A, Rieger A, Shen Z, Manhard K, Sheedy B, Hingorani V, Raney A, Nguyen M, Nguyen T, Ong V, Yeh LT, Quart B:

Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects.

Antimicrob Agents Chemotherapy 2010; 54(8):3170-8

 

137. Vogel M, Ahlenstiel G, Hintsche B, Fenske S, Trein A, Lutz T, Schurmann D, Stephan C, Khaykin P, Bickel M, Mayr C, Baumgarten A, Buggisch P, Klinker H, John C, Golz J, Staszewski S, Rockstroh JK:

The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive Individuals.

Eur J Med Res 2010; 15:102-11

 

136. Knechten H, Stephan C, Mosthaf FA, Jaeger H, Lutz T, Cargnico A, Stoehr A, Koeppe S, Mayr C, Schewe K, Wolf E, Wellmann E, Tappe A:

Safety and efficacy of a saquinavir-containing antiretroviral regimen in previously ART-naïve or pretreated but protease inhibitor-naïve HIV-positive patients.

Infection. 2010; 38 (2):108-16

 

135. Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M:

Control of cccDNA function in hepatitis B virus infection.

J Hepatol. 2009 Sep.; 51(3):581-92

 

134. Pulido F, Estrada V, Baril JG, Logue K, Schewe K, Plettenberg A, Duiculescu D, Yau L, Vavro C, Lim ML, Pharo C:

Long-Term Efficacy and Safety of Fosamprenavir plus Ritonavir Versus Lopinavir/Ritonavir in Combination with Abacavir/lamivudine over 144 Weeks.

HIV Clin Trials 2009; 10(2):76-78

 

133. Berg T, Weich V, Teuber G, Klinker H, Möller B, Rasenack J, Hinrichsen H, Pape GR, Spengler U, Buggisch P, Balk H, Zankel M, Neumann K, Sarrazin C, Zeuzem S:

Individualized Treatment Strategy with Peginterferon Alfa-2b (Peg-IFN a-2b) Plus Ribavirin According to Early Viral Kinetics in Hepatitis C Virus (HCV) Type 1-Infected Patients.

Hepatology 2009; 50 :269-377

 

132. Lorenzen T, Walther I, Stoehr A, Salzberger A, Plettenberg A of the Radata Study Group:

Effective Trearment of Patientsin an Deep Salvage Situation with Non-Active HAART: Experiences with the Expert Advice System Radata.

Infection 2009; 37 (6): 528-533

 

131. Deterding K, Wiegand J, Gruner N, Hahn A, Jackel E, Jung MC, Buggisch P, Galle; Berg T, Hinrichsen H, Potthoff A, Zeuzem S, Cornberg M, Manns M, Wedemeyer H:

The German Hep-Net Acute Hepatitis C Cohort: Impact of Viral and Host Factors on the Initial Presentation of Acute Hepatitis C Virus Infection.

Z Gastroenterol 2009; 47: 531-540

 

130. Schulze Zur Wiesch J, Pieper D, Stahmer I, Eiermann T, Buggisch P, Lohse A, Hauber J, van Lunzen J:

Sustained virological response after early antiviral treatment of acute hepatitis C virus and HIV coinfection.

Clin Infect Dis 2009; 49: 466-472

 

129. Fätkenheuer G, Staszewski S, Plettenberg A, Hackman F, Layton G, McFadyen L, Davis J, Jenkins TM:

Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients.

AIDS. 2009; 23(16):2115-22

 

128. Jansen K, Michalik C, Hahn M, Dupke S, Esser S, Jäger H, Köppe S, Moll A, Plettenberg A, Schmidt RE, Skaletz-Rorowski A, Brockmeyer NH and the Competence Network for HIV/AIDS:

The Patient Cohort of the German Competence Network for HIV/ AIDS (KompNet): A Profile.

Eur J Med Res 2009; 8: 323 - 331

 

127. Kremer H, Sonnenberg-Schwan U, Arendt G, Brockmeyer N H, Potthoff A, Ulmer A, Graefe K, Lorenzen T, Starke W, Walker U A fort he German Competence Network HIV/AIDS:

HIV or HIV-Therapy? Causal Attributions Of Symptoms And Their Impact On Treatment Decisions Among Women And Men With HIV.

EUT J Med Res 2009; 14:139-146

 

126. von Wagner M, Hofmann WP, Teuber G, Berg T, Goeser T, Spengler U, Hinrichsen H, Weidenbach H, Gerken G, Manns M, Buggisch P, Herrmann E, Zeuzem S:

Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection.

Hepatology. 2008 Nov.; 48(5):1404-11

 

125. Dandri M, Murray JM, Lutgehetmann M, Volz T, Lohse AW, Petersen J:

Virion half-life in chronic hepatitis B infection is strongly correlated with levels of viremia.

Hepatology. 2008 Oct; 48(4):1079-86

 

124. Cornberg M, Protzer U, Dollinger MM, Petersen J, Wedemeyer H, Berg T, Jilg W, Erhardt A, Wirth S, Schirmacher P, Fleig WE, Manns MP; German Society for Digestive and Metabolic Diseases; German Society for Pathology; Society for Virology; Society for Pediatric Gastroenterology and Nutrition; Competence Network for Viral Hepatitis:

The German guideline for the management of hepatitis B virus infection: short version.

J Viral Hepat. 2008 Aug; 15 Suppl 1:1-21

 

123. Petersen J, Dandri M, Mier W, Lütgehetmann M, Volz T, von Weizsäcker F, Haberkorn U, Fischer L, Pollok JM, Erbes B, Seitz S, Urban S:

Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein.

Nat Biotechnol. 2008 Mar.; 26(3):335-41. Epub 2008 Feb 24

 

122. Marcellin P, Buti M, Krastev Z, Germanidis G., Kaita K., Kotzev I, Buggisch P, Weilert F, Trinh H, Sorbel J, Anderson J., Mondou E, Quinn J, Rousseau F:

Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B.

NEJM 2008; 359: 2442-55

 

121. Halangk J, Sarrazin C, Neumann K, Puhl G, Mueller T, Teuber G, Klinker H, Hinrichsen H, Buggisch P, Landt O, Weich V, Bergk A, Wiedenmann B, Neuhaus P, Berg T, Witt H:

Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection.

J Hepatol 2008; 49:339-45

 

120. Reinel D, Plettenberg A, Seebacher C, Abeck D, Brasch J, Cornely O, Effendy I, Ginter-Hanselmeyer G, Haake N, Hamm G, Hipler U-C, Hof H, Korting H C, Mayser P, Ruhnke M, Schlacke K-H, Tietz H-J:

Leitlinie Orale Candidose.

JDDG 2008; 7: 593 - 597

 

119. Hennes EM, Oo YH, Schramm C, Denzer U, Buggisch P, Wiegard C, Kanzler S, Schuchmann M, Boecher W, Galle PR, Adams DH, Lohse AW:

Mycophenolate Mofetil as Second Line Therapy in Autoimmune Hepatitis?.

Am J Gastroenterol 2008; 103:1-8

 

118. Rodriguez-Torres M, Govindarajan S, Sola R, Clumeck N, Lissen E, Pessoa M, Buggisch P, Main J, Depamphilis J, Dieterich DT:

Hepatic steatosis in HIV/HCV co-infected patients: Correlates, efficacy and outcomes of anti-HCV therapy: A paired liver biopsy study.

J Hepatol 2008; 48:756-64

 

117. Stoehr A, Brinkmann K, Sabranski M:

Diese Leber braucht dringend eine Therapie.

MMW 2008; Sonderheft 1:54 - 57

 

116. Lutgehetmann M, Volzt T, Quaas A, Zankel M, Fischer C, Dandri M, Petersen J:

Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication.

Antivir Ther. 2008; 13(1):57-66

 

115. Cornberg M, Protzer U, Dollinger MM, Petersen J, Wedemeyer H, Berg T, Jilg W, Erhardt A, Wirth S, Schirmacher P, Fleig WE, Manns MP:

Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection.

Z Gastroenterol. 2007 Dec; 45(12):1281-328

 

114. Volz T, Lutgehetmann M, Wachtler P, Jacob A, Quaas A, Murray JM, Dandri M, Petersen J:

Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients.

Gastroenterology. 2007 Sep; 133(3):843-52

 

113. Cornberg M, Protzer U, Dollinger MM, Petersen J, Wedemeyer H, Berg T, Jilg W, Erhardt A, Wirth S, Schirmacher P, Fleig WE, Manns MP:

[Prophylaxis, Diagnosis and Therapy of Hepatitis-B-Virus-(HBV-)Infection: upgrade of the guideline, AWMF-Register 021/011].

Z Gastroenterol. 2007 Jun; 45(6):525-74

 

112. Steffen M, Cornberg M, Buggisch P:

Treatment of chronic hepatitis C with consensus interferon in relapsers and non-responders to interferon-based therapy.

Hepatogastroenterology. 2007; 54(80):2368-72

 

111. Salzberger B, Däumer M, Gute P, Jäger H, Knechten H, van Lunzen J, Mauss S, Mayr C, Moll A, Plettenberg A, Rockstroh J, Staszewski S, Stellbribk HJ, Stoll M, Stuermer M:

Enfuvirtid bei mehrfach vorbehandelten HIV-Patienten. Konsensus-Empfehlung einer deutschen Expertengruppe.

AMT 2007; 12 (25): 454 - 461

 

110. Lorenzen T, Stoehr A, Walther I, Plettenberg A:

CCR5 Antagonists in the treatment of treatment-experienced patients infectes with CCR5 tropic HIV-1.

Eur J Med Res 2007; 12: 419 - 425

 

109. Schachler E, Brockmeyer N, Effendy I, Geiss HK, Harder S, Hartmann M, Jappe U, Plettenberg A, Rasokat H, Reismann H, Shah P, Stücker M, Wichelhaus TA, Schöfer H:

Streptokokkeninfektionen der Haut und Schleimhäute.

JDDG 2007; 6: 527-532

 

108. Salzberger B, Däumer M, Gute P, Jäger H, Knechten H, van Lunzen J, Mauss S, Mayr C, Moll A, Plettenberg A, Rockstroh J, Staszewski S, Stellbrink HJ, Stoll M, Stürmer M:

Consensus recommendation from a group of German experts for the use of Enfurvitide in heavily pretreated HIV patients.

Eur J Med Res 2007; 12:93-102

 

107. Hoffmann C, Wolf E, Wyen C, Fätkenheuer G, van Lunzen J, Stellbrink H-J, Stoehr A, Plettenberg A, Jäger H, Noppeney R, Hentrich M, Goekbuget N, Hölzer D, Horst H-A:

AIDS-associated Burkitt or Burkitt-like lymphoma: Short intensive polychemotherapy is feasible and effective.

Leukemia & Lymphoma 2006 Sep.; 47(9): 1872 - 1880

 

106. Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, Longerich T, Schirmacher P, Metzler F, Zankel M, Fischer C, Currie G, Brosgart C, Petersen J:

Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.

Hepatology. 2006 Sep; 44(3):675-84

 

105. Török E, Vogel C, Lütgehetmann M, Ma PX, Dandri M, Petersen J, Burda MR, Siebert K, Düllmann J, Rogiers X, Pollok JM:

Morphological and functional analysis of rat hepatocyte spheroids generated on poly(L-lactic acid) polymer in a pulsatile flow bioreactor.

Tissue Eng. 2006 Jul; 12(7):1881-90

 

104. Dandri M, Lutgehetmann M, Volz T, Petersen J:

Small animal model systems for studying hepatitis B virus replication and pathogenesis.

Semin Liver Dis. 2006 May; 26(2):181-91

 

103. Lamarca A, Clumeck N, Plettenberg A, Domingo P, Fu K, Craig C, Zhao H, Watson M, Gordon D, Scott T:

Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL30001 Study).

J Acquir Immune Defic Syndr. 2006 Apr.; 41(5):598-606

 

102. Rathmann W, Kammal M, Schröder S, Stoehr A, Schulz F:

Chronisch fibrosierende (sklerosierende) Peritonitis als Ursache des "plötzlichen" Todes.

Rechtsmedizin 2006; 16 (2): 69-72

 

101. Stocker H, Kloft C, Plock N, Breske A, Kruse G, Herzmann C, Schulbin, Kreckel P, Weber C, Goebel F, Roeling J, Staszewski S, Plettenberg A, Moecklinghoff C, Arastéh K, Kurowski M:

Pharmacokinetics of Enfuvirtide in Patients Treated in Typical Routine Clinical Settings.

Antimicrob Agents Chemother 2006; 50(2): 667-673

 

100. Wursthorn K, Buggisch P, Lutgehetmann M, Zollner B, Petersen J:

Temporary HBV resolution in an HIV-coinfected patient during HBV-directed combination therapy followed by relapse of HBV.

Antivir Ther. 2006; 11(5):647-52

 

99. Dandri M, Petersen J:

Hepatitis B virus cccDNA clearance: killing for curing?.

Hepatology. 2005 Dec; 42(6):1453-5

 

98. Dandri M, Volz TK, Lütgehetmann M, Petersen J:

Animal models for the study of HBV replication and its variants.

J Clin Virol. 2005 Dec; 34 Suppl 1:S54-62

 

97. Fätkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelmann AIM, Saag MS, Goebel FD, Rockstroh JK, Dezube BJ, Jenkins TM, Medhurst C, Sullivan JF, Ridgway C, Abel S, James IT, Youle M & van der Ryst E:

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

Nat Med. 2005 Nov.; 11(11):1170-2. 

 

96. Hoffmann C, Tiemann M, Schrader C, Janssen D, Wolf E, Vierbuchen M, Parwaresch R, Ernestus K, Plettenberg A, Stoehr A, Fätkenheuer G, Wyen C, Oette M, Horst HA:

AIDS-related B-cell lymphoma (ARL): Correlation of prognosis with differentiation profiles assessed by immunophenotyping.

Blood 2005 May; 19 (manuscript published ahead of print)

 

95. Zöllner B, Sterneck M, Wursthorn K, Petersen J, Schröter M, Laufs R, Feucht HH:

Prevalence, incidence, and clinical relevance of the reverse transcriptase V207I mutation outside the YMDD motif of the hepatitis B virus polymerase during lamivudine therapy.

J Clin Microbiol. 2005 May; 43(5):2503-5

 

94. Meyer T, v. Krosigk A, Arndt R, Plettenberg A:

Repeated detection of Lymphogranuloma venereum caused by Chlamydia trachomatis L2 in homosexual men in Hamburg.

Sex Transm Infect. 2005 Feb.; 81(1):91-2

 

93. Dandri M, Burda MR, Zuckerman DM, Wursthorn K, Matschl U, Pollok JM, Rogiers X, Gocht A, Köck J, Blum HE, von Weizsäcker F, Petersen J:

Chronic infection with hepatitis B viruses and antiviral drug evaluation in uPA mice after liver repopulation with tupaia hepatocytes.

J Hepatol. 2005 Jan; 42(1):54-60

 

92. Plettenberg A, Stoehr A:

HIV-Postexpositionsphrophylaxe - Die aktuellen Empfehlungen auf den Punkt gebracht.

Der Deutsche Dermatologe 2005; 53 (12): 841-843

 

91. Hoffmann C, Fätkenheuer G, Wolf E, Wyen C, van Lunzen J, Stellbrink H-J, Stoehr A, Plettenberg A, Jaeger H, Noppeney R, Hentrich M, Goekbuget N, Hoelter D, Horst H-A:

AIDS-associated Burkitt - or Burkitt-like Lymphoma - improved outcome with short-term, multiagent and dose intensive regimen.

eingereicht in AIDS

 

90. Plettenberg A, v. Krosigk A, Stoehr A, Meyer T:

Four cases of lymphogranuloma venereum in Hamburg 2004.

Eurosurveillance, angenommen - Euro Surveill. 2004 Jul. 22; 8(30):35-36

 

89. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, Trepo C, Marcellin P, Goodman Z, Delaney WE 4th, Xiong S, Brosgart CL, Chen SS, Gibbs CS, Zoulim F:

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

Gastroenterology. 2004 Jun; 126(7):1750-8

 

88. Zöllner B, Petersen J, Puchhammer-Stöckl E, Kletzmayr J, Sterneck M, Fischer L, Schröter M, Laufs R, Feucht HH:

Viral features of lamivudine resistant hepatitis B genotypes A and D.

Hepatology. 2004 Jan; 39(1):42-50

 

87. Reinel D, Plettenberg A, Seebacher C, Abeck D, Brasch J, Effendy I, Ginter-Hanselmeyer G, Haake N, Hamm G, Hof H, Korting H C, Mayser P, Ruhnke M, Schlacke K.-H, Tietz H-J:

Leitlinie Orale Candidosen.

JDDG 2004; 10 : 874-876

 

86. v. Krosigk A, Meyer T, Jordan S, Graefe K, Plettenberg A, Stoehr A:

Auffällige Zunahme des Lymphogranuloma venerum unter homosexuellen Männern in Hamburg.

JDDG 2004; 8 :676-680

 

85. Albrecht D, Meyer T, Lorenzen T, Stoehr A, Arndt R, Plettenberg A:

Epidemiology of HHV-8 infection in HIV-positive patients with and without Kaposi sarcoma: diagnostic relevance and PCR.

J of Clin Virol 2004; 30:145-149

 

84. Wyen C, Hoffmann C, Schmeißer N, Wöhrmann A, Qurishi N, Rockstroh J, Esser S, Rieke A, Ross B, Lorenzen T, Schmitz K, Stenzel W, Salzberger B, Fätkenheuer G:

Progressive multifocal leukencephalopathy in patients on highly active antiretroviral therapy: survival and risk factors of death.

J AIDS 2004; 37:1263-1268

 

83. Hoffmann C, Chow KU, Wolf E, Fätkenheuer G, Stellbrink H-J, Jaeger H, Stoehr A, Plettenberg A, Wamuth JC, Rockstroh J, Mostaf F, Horst HA, Brodt H-R:

Strong impact of high active antiretroviral therapy on survival in patients Hodgkin´s disease.

Br J of Haematol 2004; 125: 455-462

 

82. Petersen J, Burda MR, Dandri M, Rogler CE:

Transplantation of human hepatocytes in immunodeficient UPA mice: a model for the study of hepatitis B virus.

Methods Mol Med. 2004; 96:253-60

 

81. Dandri M, Burda MR, Bürkle A, Zuckerman DM, Will H, Rogler CE, Greten H, Petersen J:

Increase in de novo HBV DNA integrations in response to oxidative DNA damage or inhibition of poly(ADP-ribosyl)ation.

Hepatology. 2002 Jan; 35(1):217-23

 

80. Paech V, Lorenzen T, Stoehr A, Lange K, Merz H, Meigel WN, Plettenberg A:

Remission of a cutaneous mycosis fungoides after topical 5-ALA sensitisation and photodynamic therapy in a patient with advanced HIV-infection.

Eur J Med Res 2002; 7: 477-479

 

79. Hoffmann C, Wolf E, Fätkenheuer G, Buhk T, Lorenzen T, Stoehr A, Plettenberg A, Stellbrink HJ, Jaeger H, Siebert U, Horst HA:

Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma.

AIDS 2003; 17:1521-1529

 

78. Lorenzen T, Albrecht D, Paech V, Meyer T, Hoffmann C, Stoehr A, Degen O, Stellbrink H-J, Meigel WN, Arndt R, Plettenberg A:

HHV-8 DNA in Blood and the Development of HIV- associated Kaposi´s Sarcoma in the Era of HAART - A Prospective Evaluation.

Eur J Med Res 2002; 7: 283-286

 

77. Paech V, Lorenzen T, Stoehr A, Plettenberg A:

RADATA - implementation of resistance analysis and expert advice for optimized HAART switches in general practice of HIV-infected individuals via a compiling internet presence.

Eur J Med Res 2002; 7: 323-329

 

76. Albrecht D, Zöllner B, Feucht H-H, Lorenzen T, Laufs R, Stoehr A, Plettenberg A:

Reappearance of HIV multidrug-resistance in plasma and circulating lymphocytes after reintroduction of antiretroviral therapy.

J Virol 2002; 24: 93-98

 

75. Paech V, Lorenzen T, v. Krosigk A, Graefe K, Stoehr A, Plettenberg A:

Gynaecomastia in HIV-infected men: association with effects of antiretroviral therapy.

AIDS 2002, 16: 1193-5

 

74. Paech V, Lorenzen T, Stoehr A, Plettenberg A:

Adherence to HAART: Why it is so difficult?.

Arch Intern Med 2002; 162: 1197

 

73. Paech V, Lorenzen T, v.Krosigk A, v.Stemm A, Meigel WA, Stoehr A, Rüsch-Gerdes S, Richter E, Plettenberg A:

Remission of Cutaneous Mycobacterium haemophilum Infection as a Result of Antiretroviral Therapy in a Human Immunodeficiency Virus-Infected Patient.

Clin Inf Dis 2002; 34: 1017-9

 

72. Stoehr A, Paech V, Lorenzen T, v. Krosigk A, Graefe K, Plettenberg A:

Wandel der Guidelines zur Prophylaxe opportunistischer Infektionen im Zeitalter HAART.

In: AIDS, Herausgeber: Hoffmann, Jäger. Verlag moderne Industrie, 2002

 

71. Paech V, Lorenzen T, Stoehr A, Plettenberg A:

RADATA - ein Projekt zur Optimierung antiretroviraler Therapieentscheidungen.

In: AIDS, Herausgeber: Hoffmann, Jäger. Verlag moderne Industrie, 2002

 

70. Zöllner B, Schäfer P, Feucht HH, Schröter M, Petersen J, Laufs R:

Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy.

J Med Virol. 2001 Dec; 65(4):659-63

 

69. Burda MR, Günther S, Dandri M, Will H, Petersen J:

Structural and functional heterogeneity of naturally occurring hepatitis B virus variants.

Antiviral Res. 2001 Nov; 52(2):125-38

 

68. Petersen J, Ott M, von Weizsäcker F:

[Current status of cell-based therapies in liver diseases].

Z Gastroenterol. 2001 Nov; 39(11):975-80

 

67. Dandri M, Burda MR, Gocht A, Török E, Pollok JM, Rogler CE, Will H, Petersen J:

Woodchuck hepatocytes remain permissive for hepadnavirus infection and mouse liver repopulation after cryopreservation.

Hepatology. 2001 Oct; 34(4 Pt 1):824-33

 

66. Dandri M, Burda MR, Török E, Pollok JM, Iwanska A, Sommer G, Rogiers X, Rogler CE, Gupta S, Will H, Greten H, Petersen J:

Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus.

Hepatology. 2001 Apr; 33(4):981-8

 

65. Zöllner B, Petersen J, Schröter M, Laufs R, Schoder V, Feucht HH:

20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw.

Lancet. 2001 Mar 24; 357(9260):934-5

 

64. Weitzel T, Arasteh K, Rockstroh J , Schmidt W, Jablonowski H, Emminger C, Bogner JR, Brockmeyer N, Stoehr A, Baumgarten R, Schmidt RE , Plettenberg A:

Aspergillosen bei HIV-Patienten.

Med Review 2001; 7: 8-12

 

63. Plettenberg A, Albrecht D, Lorenzen T, Meyer T, Arndt R, Stoehr A:

Monitoring of endogenous Interferon-alpha and human herpesvirus 8 in HIV-infected patients with kaposi´s sarcoma.

Eur J Med Res 2001; 6: 1-9

 

62. Plettenberg A, Albrecht D, Lorenzen T, Paech V, Petersen H, Fenner T, Meyer T, Arndt R, Hertogs K, Pauwels R, Weitzel T, Stoehr A:

Resistance analyses in HIV infected patients with a history of multiple antiretroviral treatment regimens.

STI 2001; 77: 449-452

 

61. Hoffmann C, Tabrizian S, Wolf E, Eggers C, Stoehr A, Plettenberg A, Buhk T, Stellbrink HJ, Horst HA, Jäger H, Rosenkranz T:

Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery.

AIDS 2001; 15: 2119-2127

 

60. Zöllner B, Feucht HH, Schröter M, Schäfer P, Plettenberg A, Stoehr A, Laufs R:

Primary genotypic resistance of HIV-1 to the fusion inhibitor T-20 in long-term infected patients.

AIDS 2001; 15:933-937

 

59. Szeimies RM, Lorenzen T, Abels C, Bäumler W, Landthaler M, Meigel W, Plettenberg A:

Photochemotherapie kutaner Kaposi-Sarkome mit Indocyaningrün.

Hautarzt 2001; 52:322-326

 

58. Dandri M, Burda MR, Will H, Petersen J:

Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA.

Hepatology. 2000 Jul; 32(1):139-46

 

57. Plettenberg A, Lorenzen T, Burtsche B, Rasokat H, Kaliebe T, Albrecht H, Mertenskötter T, Bogner JR, Stoehr A, Schöfer H:

Bacillary angiomatosis in HIV-infected patients- an epidemiological and clinical study.

Dermatol 2000; 201: 326-331

 

56. Zöllner B, Stoehr A, Plettenberg A, Feucht HH, Schröter M, Schäfer P, Laufs R:

In vivo dynamics and pathogenicity of wild-type and resistant hepatitis B virus during long-term lamivudine monotherapy.

J Clin Virol 2000; 17:183-188

 

55. Richter E, Gerdes S-R, Niemann S, Stoehr A, Plettenberg A:

Detection, identification, and treatment of a novel, non-cultivable Mycobacterium species in a HIV patient.

AIDS 2000; 14:1667-1668

 

54. Katlama C, Clotet B, Plettenberg A, Jost J, Arastheh K, Bernasconi E, Jeantils V, Cutrell A, Stone C, Ait-Khaled M, Purdon S:

The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients. Results from a randomised, double-blind trial.

AIDS 2000; 14: 781-789

 

53. Albrecht D, Lorenzen T, Stoehr A, Jarke J, Plettenberg A:

Studie zur postsexuellen HIV-Expositionsprophylaxe.

Bundesgesundheitsblatt 2000; 43 (Suppl 1): 54-59

 

52. Weitzel T, Arasteh K, Bogner RJ, Schmidt W, Stoehr A, Rockstroh JK, Schmidt RE, Stellbrink HJ, Brockmeyer N, Emminger C, Hartmann M, Baumgatner R, Jablonowski H, Schöfer H, Plettenberg A:

Kryptokokkosen bei HIV-positiven Patienten in Deutschland- eine Auswertung 14 deutscher HIV-Zentren.

In: HIV-Infekt, Herausgeber: Brockmeyer, Brodt, Hoffmann, Reimann, Stücker, Altmeyer. Springer Verlag, 1999; 548-553

 

51. Albrecht D, Meyer T, Lorenzen T, Stoehr A, Meigel W, Arndt A, Plettenberg A:

Serologie und PCR in der HHV-8 Diagnostik.

In: HIV-Infekt, Herausgeber: Brockmeyer, Brodt, Hoffmann, Reimann, Stücker, Altmeyer. Springer Verlag, 1999; 512-517

 

50. Plettenberg A, Albrecht D, Lorenzen T, Jarke J, Stoehr A:

Postsexuelle HIV-Expositionsprophylaxe- Beschreibung einer kontrollierten Studie und Präsentation erster Ergebnisse.

In: HIV-Infekt. Herausgeber: Brockmeyer, Brodt, Hoffmann, Reimann, Stücker, Altmeyer. Springer Verlag, 1999; 160-162

 

49. Lorenzen T, Weitzel T, Krosigk A, Albrecht D, Stoehr A, Plettenberg A:

Kutane Nebenwirkungen unter Nevirapin-Therapie bei HIV-positiven Patienten.

In: HIV-Infekt, Hrs: Brockmeyer, Brodt, Hoffmann, Reimann, Stücker, Altmeyer, Springer Verlag, 1999; 488-491

 

48. Husstedt IW, Plettenberg A, Reichelt D, Schmidt RE, Stoehr A, Sutor G-C, Träder C:

Klinischer Erfahrungsbericht über den Einsatz von Atovaquon als Compassionate-Use-Programm. Behandlung und Prophylaxe der cerebralen oder okulären Toxoplasmose bei Patienten mit AIDS.

Nervenheilkunde 1999; 18:260-263

 

47. Plettenberg A, Lorenzen T, Stoehr A, Adam A, Weitner L, Hoffmann C, Carstensen C, Tsialsudis B, Chorselski G, Meyer-Thompson HG, van Lunzen J, Meyer A, Aries SP, Peters M, Fenske S, Sudeck H, Schmidt R:

Aktueller Stand der antiretroviralen Therapie bei HIV-infizierten drogenabhängigen Patienten im Großraum Hamburg.

Hamburger Ärzteblatt 1999; 5: 214-217

 

46. Weitzel T, Plettenberg A, Albrecht D, Lorenzen T, Stoehr A:

Severe anaemia as a recognized side-effect caused by lamivudine.

AIDS 1999; 13: 2310-11

 

45. Plettenberg A, Stoehr A, Heise W, Schlote F, Sarnow E, Migdal M:

Efficacy, safety and toleration of fluconazole suppositories in the treatment of oral candidiasis.

Mycoses 1999; 42: 269-72

 

44. Stoehr A, Arasteh K, Staszewski S, Brockmeyer N, Albrecht H, Mertenskötter T, Jablonski H, Emminger C, Rockstroh JK, Baumgarten R, Bogner J, Loch T, Plettenberg A:

Pneumocystis carinii Pneumonia in the Federal Republic of Germany in the Era of changing antiretroviral therapy - IdkF 13.

Eur J Med Res 1999; 4: 131-134

 

43. Dandri M, Petersen J, Stockert RJ, Harris TM, Rogler CE:

Metabolic labeling of woodchuck hepatitis B virus X protein in naturally infected hepatocytes reveals a bimodal half-life and association with the nuclear framework.

J Virol. 1998 Nov; 72(11):9359-64

 

42. Petersen J, Dandri M, Gupta S, Rogler CE:

Liver repopulation with xenogenic hepatocytes in B and T cell-deficient mice leads to chronic hepadnavirus infection and clonal growth of hepatocellular carcinoma.

Proc Natl Acad Sci U S A. 1998 Jan 6; 95(1):310-5

 

41. Albrecht H, Hoffmann C, Degen O, Stoehr A, Plettenberg A, Mertenskötter T, Eggert C, Stellbrink H-J:

Highly active antiretroviral therapy (HAART) significantly improves the prognosis of patients (pts.) with HIV-associated progressive multifocal leukencephalopathy.

AIDS 1998; 112:1149-1154

 

40. Meyer T, Kunz M, Arndt R, Meigel W, Stoehr A, Plettenberg A:

Detection of HPV 35 in a nodular cutaneus tumor of an HIV-infected patient.

CID 26: 507-508, 1998

 

39. Petersen J, Dandri M, Bürkle A, Zhang L, Rogler CE:

Increase in the frequency of hepadnavirus DNA integrations by oxidative DNA damage and inhibition of DNA repair.

J Virol. 1997 Jul; 71(7):5455-63

 

38. Lorenzen T, Kunz M, Meyer T, Degen O, Lenzner U, Albrecht H, Stellbrink H-J, Stoehr A,   Arndt R, Meigel W, Plettenberg A:

Humanes Herpesvirus 8 und Kaposi Sarkom - Analyse des peripheren Blutes von 237 HIV-positiven Patienten auf HHV 8-DNA mittels nested-PCR sowie die prospektive Nachbeobachtung hinsichtlich dem Auftreten von Kaposi Sarkomen.

In: AIDS: Neue Perspektiven Therapeutische Erwartungen Die Realität 1997. AIDS-Monographien, Band 3. Herausgeber: Jäger H, Ecomed Landsberg, München, Zürich 121, 1997

 

37. Plettenberg A:

Bazilläre Angiomatose.

In: AIDS: Neue Perspektiven Therapeutische Erwartungen Die Realität 1997. AIDS-Monographien, Band 3. Herausgeber: Jäger H, Ecomed Landsberg, München, Zürich 121, 1997

 

36. Plettenberg A, v Dyk U, Stoehr A, Albrecht H, Stellbrink HJ, Berger J, Meigel W:

Increased risk for opportunistic infection during chemotherapy in patients with Kaposi's sarcoma.

Dermatol 194: 234-237, 1997

 

35. Bogner J. R., S. Rüsch-Gerdes, T. Mertenskötter, O. Loch, C. Emminger, Baumgarten N. H. Brockmeyer, W. Brockhaus, H. Jablonowski, A. Stoehr, H. Albrecht, W. K. Roth, S. Tschauder, A. Roth, M. Dietrich:

Patterns of M. avium culture and PCR postivity in HIV-infected patients with less than 100 CD4 cells: Progression from localized to systemic disease.

Scand J Infect Dis. 1997; 29(6):579-84

 

34. Plettenberg A, Pammer J, Tschachler E:

Merkel cells and Merkel cell carcinoma express the BCL-2 proto-oncogene.

Exp Dermatol 5: 102-107; 1996

 

33. Salzberger B, A. Stoehr, H. Jablonowski, U. Ewald, K. Peters, G.Fätkenheuer, M.Schrappe:

Foscarnet 5 versus 7 Days a Week Treatment for severe Gastrointestinal CMV Disease in HIV- Infected Patients.

Infection 24: 121-124, 1996

 

32. Weninger W, Uthman A, Pammer J, Pichler A, Ballaun C, Lang I, Plettenberg A, Bankl H, Stürzl M, Tschachler E:

Vascular endothelial growth factor production in normal epidermis and in benign and malignant epithelial skin tumors.

Lab Invest 75:647-658, 1996

 

31. Schöfer H, Imhof M, Thoma-Greber E, Brockmeyer NH, Hartmann M, Gerken G, Pees HW, Rasokat H, Hartmann H, Sadri I, Emminger C, Stellbrink HJ, Baumgarten R, Plettenberg A. The German AIDS Study Group (GASG):

Active syphilis in HIV infection: a multicentre retrospective survey.

Genitourin Med 72:176-181, 1996

 

30. Pammer J, Plettenberg A, Weninger W, Diller B, Mildner M, Uthman A, Issing W, Stürzl M, Tschachler E:

CD40 antigen is expressed by endothelial cells and tumor cells in kaposi`s sarcoma.

Am J Pathol 5:1387-1396, 1996

 

29. German AIDS Study Group GASG/IdKF:

Observational Analysis of German Injecting Drug Users (IDU): Survival with and without Methadone Maintenance Treatment.

Eur J Med Res 1: 209- 214, 1995/96

 

28. The Oral Ganciclovir European and Australian Cooperative Study Group:

Intravenous versus oral ganciclovir: European/Australian: comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis in patients with AIDS.

AIDS 9: 471- 477, 1995

 

27. Plettenberg A, Tronnier M, Kreusch J, Wolff HH, Meigel W:

Bazilläre Angiomatose.

Hautarzt 46:39-43, 1995

 

26. Harloff KJ, Stoehr A, Waßmuth R, Plettenberg A, Harten J:

Pulmonale Mucormykose bei einem HIV-infizierten Patienten.

Deutsche Medizinische Wochenschrift 120:94-98, 1995

 

25. Salzberger B., M. Schrappe, A. Stoehr, L. Mantovani, A. Hiersche, A. Schwenk, C.Franzen, G.Fätkenheuer:

Foscarnet and Ganciclovir Combination Therapy for CMV Disease in HIV-Infected Patients.

Infection 22: 197- 200, 1994

 

24. Stoehr A, Plettenberg A, Albrecht H, Stellbrink HJ, Meigel W, Begemann F:

Primäre und sekundäre Prophylaxe der Pneumocystis-carinii-Pneumonie mit Pentamidin-Aerosol. Wirksamkeit, Nebenwirkungen und Häufigkeit der extrapulmonalen Pneumocystis-carinii-Manifestation.

Medizinische Klinik 89:132-135, 1994

 

23. Albrecht H, Helm EB, Plettenberg A, Emminger C, Heise W, Schwartländer B, Stellbrink HJ:

Kaposi's sarcoma in HIV infected women in Germany: more evidence for sexual transmission. A report of 10 cases and review of the literature.

Genitourin Med 70:394-398, 1994

 

22. Tronnier M, Plettenberg A, Meigel W, Wolff HH:

Recurrent verrucous herpes zoster in an HIV patient. Demonstration of the virus by immunofluorescence and electron microscopy.

Eur J of Dermatol 4:604-607, 1994

 

21. Plettenberg A, Stoehr A, Höffken G, Bergs C, Tschechne B, Ruhnke M, Heise W, Dieckmann S, Meigel W:

Fluconazole therapy of oral candidiasis in HIV-infected patients: Results of a multicentre study.

Infection 22:118-124, 1994

 

20. Stellbrink, H. J., R. Averdunk, A. Stoehr, H. Albrecht:

Zidovudine Half-Life in Hemodialysis Patients.

AIDS 7: 141- 142, 1993

 

19. Stellbrink HJ, Albrecht H, Plettenberg A, Stoehr A, Laufs R, Fenske S, Greten H:

Antiviral and immunological effects of escalating low doses of zidovudine in HIV-positive patients.

Eur J Clin Microbiol Infect Dis 12:618-621, 1993

 

18. Garweg J, Olszowski W, Knospe V, Stoehr A, Plettenberg A, Albrecht H, Stellbrink HJ, Weitner L, Dietrich M:

Zur Sekundärprophylaxe der Zytomegalieretinitis mit Ganciclovir.

Der Ophthalmologe 90:267-273, 1993

 

17. Plettenberg A, Stoehr A, Stellbrink HJ, Albrecht H, Meigel W:

Preparation from bovine colostrum in the treatment of HIV-positive patients with chronic diarrhea.

Clin Investig 71:42-45, 1993

 

16. Stoehr A, Plettenberg A, Waßmuth R, Begemann F, Knospe V, Schrappe M, Salzberger B, Heise W:

Kombinierte Induktionstherapie der Cytomegalie-Virus-Erkrankung bei AIDS-Patienten mit 50% Foscarnet und 50 % Ganciclovir.

In: AIDS: Eine Krankheit wird behandelbar. Materialien zur HIV-Erkrankung im 2. Jahrzehnt. AIDS-Monographien, Band 3. Herausgeber: Jäger H, Ecomed Landsberg, München, Zürich 97-99, 1993

 

15. Stoehr A, Plettenberg A, Begemann F, Heise W, Höffken G:

Therapie der Soorösophagitis mit Fluconazol bei AIDS-Patienten. Eine offene nicht vergleichende Studie.

Chemotherapie Journal 1:116-119, 1992

 

14. Laufs R, Schulz WD, Ermer M, Stellbrink J, Plettenberg A:

Die Bedeutung des Antikörper- und Antigennachweises sowie der Virusisolierung für die Verlaufsbeurteilung der HIV-Infektion.

Hamburger Ärzteblatt 45:124-127, 1991

 

13. Stoehr A:

Pentamidin-Aerosol, prophylaktischer und therapeutischer Einsatz bei HIV-Patienten.

Arzneimitteltherapie, 9: 35- 37, 1991

 

12. Plettenberg A, Gilgen K, Stoehr A, Meigel W:

CD4-Lymphozyten bei Erstmanifestation des HIV-assoziierten Kaposi-Sarkoms - Zunehmender Immundefekt zum Zeitpunkt der Erstmanifestation?.

Aktuelle Dermatologie 17:276-277, 1991

 

11. Plettenberg A, Nilsson M, Bahlmann W, Franke C, Stoehr A, Arndt R, Baumann B, Laufs R, Meigel W:

Einfluss von alfa-2b-Interferon auf prognostische Parameter und auf klinische Ereignisse bei HIV-positiven Patienten in den Stadien LAS/ ARC.

Medizinische Klinik 86:555-560, 1991

 

10. Plettenberg A, Bahlmann W, Stoehr A, Meigel W:

Klinische und serologische Befunde der Lues bei HIV-infizierten Patienten.

Deutsche Medizinische Wochenschrift 116:968-972, 1991

 

9. Plettenberg A, Janik I, Kolb H, Meigel W:

Lokaltherapeutische Maßnahmen beim HIV-assoziierten Kaposi-Sarkom mit besonderer Berücksichtigung der Röntgenweichstrahltherapie.

Strahlentherapie und Onkologie 167:208-213, 1991

 

8. Plettenberg A, Kern P, Dietrich M, Meigel W:

Rekombinantes Interferon alfa 2A in der Behandlung des HIV-assoziierten Kaposi-Sarkoms. Langzeitergebnisse.

Medizinische Klinik 85:647-652, 1990

 

7. Plettenberg A, Reisinger E, Lenzner U, Listemann H, Ernst M, Kern P, Dietrich M, Meigel W:

Oral candidosis in HIV-infected patients. Prognostic value and correlation with immunological parameters.

Mycoses 33:421-425, 1990

 

6. Plettenberg A, Kern P, Klare A, Dietrich M, Meigel W:

HIV-associated Kaposi's sarcoma treated with recombinant interferon alfa-2a. Long-term results.

In: Cytokines in Hemopoesis, Oncology, and AIDS. Herausgeber: Freund M, Link H, Welte K, Springer Verlag Berlin, Heidelberg, New York, London, Paris, Tokyo, HongKong 631-637, 1990

 

5. Plettenberg A, Füzesi S, Meigel W:

Exazerbation einer HIV-assoziierten psoriasiformen Dermatitis unter Interferon alfa-2a-Therapie bei einem HIV-positiven Patienten mit Kaposi-Sarkom.

Aktuelle Dermatologie 16:112-115, 1990

 

4. Plettenberg A, Engelmann L, Meigel W:

Pathogenese des HIV-assoziierten Kaposi-Sarkoms - das Köbner-Phänomen als möglicher Auslösemechanismus.

H+G Zeitschrift für Hautkrankheiten 65:684-689, 1990

 

3. Reisinger E, Dettke T, Plettenberg A, Ernst M, Schwander S, Dörlemann A, Winzer M, Kern P, Meigel W, Dietrich M:

Prognostische Bedeutung der oralen Haarleukoplakie (HL) und therapeutische Konsequenzen - Erkenntnisse im Rahmen einer prospektiven HIV-Therapiestudie.

Mitteilungen der Österreichischen Gesellschaft für Tropenmedizin und Parasitologie 11:359-364, 1989

 

2. Plettenberg A, Schwartau M, Meyer E, Kuse R, Hanrath P:

Kardiale Beteiligung beim hypereosinophilen Syndrom. Bedeutung der Echokardiographie in der Diagnostik seltener Erkrankungen.

Herz Kreislauf 1988, 20:360-363

 

1. Becher H, Plettenberg A, Hanrath P, Bleifeld W, Bleese N:

Herzoperationen bei akuter bakterieller Endokarditis ohne präoperative Herzkatheterisierung.

Deutsche Medizinische Wochenschrift 1987,112:498-503